Inovio Pharmaceuticals, Inc.INO

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$1.21
Market cap
$125.1M
P/E
—
Revenue (TTM)
$0
Net income
-$67.4M
Dividend yield
—
1-year total return
-50.2%
Net margin
—
Revenue growth
-100.0%
Debt / equity
—

What Inovio Pharmaceuticals, Inc. does.

This Annual Report on Form 10-K (including the following section regarding Management’s Discussion and Analysis of Financial Condition and Results of Operations), or this Annual Report, contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters, including statements regarding our business, our financial position, the research and development of our products and other statements regarding matters that are not historical are forward-looking statements.

Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$7.4M$1.8M$10.3M$832,010$217,756$65,343
Net income-$166.4M-$303.7M-$279.8M-$135.1M-$107.3M-$84.9M
Free cash flow-$179.5M-$216.9M-$217.2M-$124.7M-$104.6M-$88.9M

More on INO.

Figures from Inovio Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.